Oxidative stress in experimental liver microvesicular steatosis: Role of mitochondria and peroxisomes

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 8, 2006, Pages 1240-1249

  Natarajan, Sathish Kumar ^a   Eapen, Chundamannil E ^a   Pullimood, Anna B ^a   Balasubramanian, Kunissery A ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Microvesicular steatosis; Mitochondria; Oxidative stress; Peroxisome proliferators activator receptor alpha (PPAR ); Valproate

Indexed keywords

ETHANOLAMINE; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; LIPID ANALYSIS; LIPID PEROXIDATION; MICROSOME; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PEROXISOME; PRIORITY JOURNAL; RAT;

EID: 33745844419     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04313.x     Document Type: Article

References (49)

1. Hautekeete ML, Degott C, Benhamou JP. Microvesicular steatosis of the liver. Acta Clin. Belg. 1990; 45: 311-26.
2. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995; 67: 101-54.
3. Mannaerts GP, Debeer LJ, Thomas J, De Schepper PJ. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J. Biol. Chem. 1979; 254: 4585-95.
4. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 1999; 15: 367-73.
5. Geneve J, Hayat-Bonan B, Labbe G et al. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J. Pharmacol. Exp. Ther. 1987; 242: 1133-7.
6. Treem WR, Rinaldo P, Hale DE et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Hepatology 1994; 19: 339-15.
7. Rolfes DB, Ishak KG. Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology 1985; 5: 1149-58.
8. Fromenty B, Grimbert S, Mansouri A et al. Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis. Gastroenterology 1995; 108: 193-200.
9. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver Dis. 2001; 21: 43-55.
10. Xu S, Zhu BT, Conney AH. Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes. J. Pharmacol. Exp. Ther. 2001; 296: 188-97.
11. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984; 4: 1143-52.
12. Guerra FC. Rapid isolation techniques for mitochondria: technique for rat liver mitochondria. Methods Enzymol. 1974; 31: 299-305.
13. Umeda-Sawada R, Ogawa M, Nakamura M, Igarashi O. Effect of sesamin on mitochondrial and peroxisomal beta-oxidation of arachidonic and eicosapentaenoic acids in rat liver. Lipids 2001; 36: 483-9.
14. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. Ii. Solubilization, purification, and properties. J. Biol. Chem. 1964; 239: 2379-85.
15. Pennington RJ. Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem. J. 1961; 80: 649-54.
16. Aebi H. Catalase in vitro. Methods Enzymol. 1984; 105: 121-6.
17. Dawkins MJ. Changes in glucose-6-phosphatase activity in liver and kidney at birth. Nature 1961; 191: 72-3.
18. Madesh M, Ramachandran A, Balasubramanian KA. Nitric oxide prevents anoxia-induced apoptosis in colonic HT29 cells. Arch. Biochem. Biophys. 1999; 366: 240-8.
19. Takeyama N, Matsuo N, Tanaka T. Oxidative damage to mitochondria is mediated by the Ca (2+) -dependent inner-membrane permeability transition. Biochem. J. 1993; 294 (Pt 3): 719-25.
20. Madesh M, Bhaskar L, Balasubramanian KA. Enterocyte viability and mitochondrial function after graded intestinal ischemia and reperfusion in rats. Mol. Cell. Biochem. 1997; 167: 81-7.
21. Scarpa A. Measurements of cation transport with metallochromic indicators. Methods Enzymol. 1979; 56: 301-38.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979; 95: 351-8.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Med. Sci. 1959; 37: 911-17.
24. Chan HW, Levett G. Autoxidation of methyl linoleate. Separation and analysis of isomeric mixtures of methyl linoleate hydroperoxides and methyl hydroxylinoleates. Lipids 1977; 12: 99-104.
25. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999; 300: 58-62.
26. Sohal RS, Agarwal S, Dubey A, Orr WC. Protein oxidative damage is associated with life expectancy of houseflies. Proc. Natl Acad. Sci. USA 1993; 90: 7255-9.
27. Habeeb AFSA. Reaction of protein sulfhydryl groups with Ellman's reagent. Methods Enzymol. 1972; 25: 457-64.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
29. Zlatkis A, Zak B, Boyle AJ. A new method for the direct determination of serum cholesterol. J. Lab. Clin. Med. 1953; 41: 486-92.
30. Snyder F, Stephens N. A simplified spectrophotometric determination of ester groups in lipids. Biochim. Biophys. Acta 1959; 34: 244-5.
31. Bartlett GR. Phosphorus assay in column chromatography. J. Biol. Chem. 1959; 234: 466-8.
32. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J. Hepatol. 1997; 26 (Suppl. 1): 13-22.
33. Matern D, Hart P, Murtha AP et al. Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. J. Pediatr. 2001; 138: 585-8.
34. Miyazawa S, Furuta S, Hashimoto T. Reduction of beta-oxidation capacity of rat liver mitochondria by feeding orotic acid. Biochim. Biophys. Acta 1982; 711: 494-502.
35. Freneaux E, Labbe G, Letteron P et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8: 1056-62.
36. Keller BJ, Yamanaka H, Thurman RG. Inhibition of mitochondrial respiration and oxygen-dependent hepatotoxicity by six structurally dissimilar peroxisomal proliferating agents. Toxicology 1992; 71: 49-61.
37. Deschamps D, DeBeco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994; 19: 948-61.
38. Lewis JH, Zimmerman HJ, Garrett CT, Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982; 2: 870-3.
39. Baldwin GS, Abbott FS, Nau H. Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett. 1996; 384: 58-60.
40. Hashimoto T, Fujita T, Usuda N et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J. Biol. Chem. 1999; 274: 19 228-36.
41. Tserng KY, Jin SJ, Kerr DS, Hoppel CL. Urinary 3-hydroxydicarboxylic acids in pathophysiology of metabolic disorders with dicarboxylic aciduria. Metabolism 1991; 40: 676-82.
42. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J. Hepatol. 1996; 24: 200-8.
43. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991; 11: 81-128.
44. Madesh M, Balasubramanian KA. Activation of liver mitochondrial phospholipase A2 by superoxide. Arch. Biochem. Biophys. 1997; 346: 187-92.
45. Chen C, Hennig GE, Whiteley HE, Corton JC, Manautou JE. Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol. Sci. 2000; 57: 338-14.
46. Manautou JE, Silva VM, Hennig GE, Whiteley HE. Repeated dosing with the peroxisome proliferator clofibrate decreases the toxicity of model hepatotoxic agents in male mice. Toxicology 1998; 127: 1-10.
47. Shin M, Iwamoto N, Yamashita M, Sano K, Umezawa C. Pyridine nucleotide levels in liver of rats fed clofibrate- or pyrazinamide-containing diets. Biochem. Pharmacol. 1998; 55: 367-71.
48. Moody DE, Reddy JK. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes. Am. J. Pathol. 1978; 90: 435-50.
49. Novikoff PM, Edelstein D. Reversal of orotic acid-induced fatty liver in rats by clofibrate. Lab. Invest. 1977; 36: 215-31.